| Putting National Institute for Health and Clinical Excellence guidance into practice: A cost minimization model of a national roll-out of liquid based cytology in England / | Stoykova, Boyka ;, Kuzmanov, Georgi ;, Dowie, Robinorgi ; | 391-398 | 2008.10.27 | - | |
| Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: A prospective, randomized study / | Joffe, Grigori ;, Sintonen, Harri ;, Appelberg, Bjorn; | 399-402 | 2008.10.27 | - | |
| Guidance for considering ethical, legal, and social issues in health technology assessment: Application to genetic screening / | Potter, Beth K. et al | 412-422 | 2008.10.27 | - | |
| Reuse of single use medical devices in Canada: Clinical and economic outcomes, legal and ethical issues, and current hospital practice / | Hailey, David. et al | 430-436 | 2008.10.27 | - | |
| Economic evaluations conducted by Canadian health technology assessment agencies: Where do we stand? / | Tarride, Jean-Eric. et al | 437-444 | 2008.10.27 | - | |
| Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach / | Vallejo-Torres, Laura. et al | 459-464 | 2008.10.27 | - | |
| Health technology assessment use and dissemination by patient and consumer groups: Why and how? / | Fattal, Julie ;, Lehoux, Pascale | 473-480 | 2008.10.27 | - | |
| Do individuals consider expected income when valuing health states? / | Davidson, Thomas ;, Levin, Lars-Ake | 488-494 | 2008.10.27 | - | |
| Budgeting and health technology assessment: First evidence obtained from proposal forms used to submit the adoption of new technology / | Lettieri, Emanuele ;, Masella, Cristina ;, Nocco, Umbertoina ; | 502-510 | 2008.10.27 | - | |
